PMID- 38315832
OWN - NLM
STAT- Publisher
LR  - 20240205
IS  - 2473-9537 (Electronic)
IS  - 2473-9529 (Linking)
DP  - 2024 Feb 5
TI  - Outcomes of subsequent anti-lymphoma therapies after second-line axicabtagene 
      ciloleucel or standard of care in ZUMA-7.
LID - bloodadvances.2023011532 [pii]
LID - 10.1182/bloodadvances.2023011532 [doi]
AB  - In ZUMA-7 (NCT03391466), axicabtagene ciloleucel (axi-cel) significantly improved 
      outcomes versus second-line (2L) standard of care (SOC) for adults with 
      relapsed/refractory large B-cell lymphoma (LBCL). The optimal management of 
      patients after disease progression or lack of response to 2L therapy remains 
      unclear. Here, we report outcomes among patients who received subsequent 
      anti-lymphoma therapy per investigator discretion separately by their randomized 
      2L arm in ZUMA-7. Progression-free survival (PFS) and overall survival (OS) were 
      calculated from 3L therapy initiation by randomized 2L arm. In the SOC arm, 
      127/179 randomized patients (71%) received 3L therapy. Median PFS among those who 
      received 3L cellular immunotherapy (n=68) versus those who did not (n=59) was 6.3 
      versus 1.9 months, respectively; median OS was 16.3 versus 9.5 months, 
      respectively. In the axi-cel arm, 84/180 randomized patients (47%) received 3L 
      therapy. Median PFS among those who received 3L chemotherapy (n=60) versus 
      cellular immunotherapy (n=8) was 1.7 versus 3.5 months, respectively; median OS 
      was 8.1 months versus not reached, respectively. Of the 60 patients who received 
      3L chemotherapy, 10 underwent stem cell transplantation (SCT; 9 autologous; 1 
      allogeneic) after salvage chemotherapy. Median PFS was 11.5 versus 1.6 months, 
      and median OS was 17.5 versus 7.2 months for those who did versus those who did 
      not reach SCT, respectively. Eight patients received 3L cellular immunotherapy 
      after 2L axi-cel. Of these, 6 patients received subsequent SCT in any line, and 
      all 6 were alive at data cutoff. These findings help inform subsequent treatment 
      choices after failure of 2L therapy for relapsed/refractory LBCL.
CI  - Copyright (c) 2024 American Society of Hematology.
FAU - Ghobadi, Armin
AU  - Ghobadi A
AUID- ORCID: 0000-0001-8848-8474
AD  - Washington University in St. Louis, St. Louis, Missouri, United States.
FAU - Munoz, Javier
AU  - Munoz J
AUID- ORCID: 0000-0002-9060-8911
AD  - Banner MD Anderson Cancer Center, Gilbert, Arizona, United States.
FAU - Westin, Jason R
AU  - Westin JR
AUID- ORCID: 0000-0002-1824-2337
AD  - The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United 
      States.
FAU - Locke, Frederick L
AU  - Locke FL
AD  - Moffitt Cancer Center, Tampa, Florida, United States.
FAU - Miklos, David B
AU  - Miklos DB
AUID- ORCID: 0000-0003-0717-4305
AD  - Stanford University Medical School, Stanford, California, United States.
FAU - Rapoport, Aaron P
AU  - Rapoport AP
AD  - University of Maryland, Baltimore, Maryland, United States.
FAU - Perales, Miguel-Angel
AU  - Perales MA
AUID- ORCID: 0000-0002-5910-4571
AD  - Memorial Sloan Kettering Cancer Center, New York, New York, United States.
FAU - Reagan, Patrick M
AU  - Reagan PM
AD  - University of Rochester Medical Center, Rochester, New York, United States.
FAU - McGuirk, Joseph P
AU  - McGuirk JP
AUID- ORCID: 0000-0002-0539-4796
AD  - University of Kansas Cancer Center, Westwood, Kansas, United States.
FAU - Jacobson, Caron A
AU  - Jacobson CA
AD  - Dana-Farber Cancer Institute, Boston, Massachusetts, United States.
FAU - Kersten, Marie Jose
AU  - Kersten MJ
AD  - Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.
FAU - Avivi, Irit
AU  - Avivi I
AD  - Tel Aviv Sourasky Medical Center and Tel Aviv University, Tel Aviv, Israel.
FAU - Peng, Andrew
AU  - Peng A
AD  - Kite, a Gilead Company, Santa Monica, California, United States.
FAU - Schupp, Marco
AU  - Schupp M
AD  - Kite, a Gilead Company, Santa Monica, California, United States.
FAU - To, Christina
AU  - To C
AD  - Kite, A Gilead Company, Santa Monica, California, United States.
FAU - Oluwole, Olalekan O
AU  - Oluwole OO
AUID- ORCID: 0000-0001-8525-9641
AD  - Vanderbilt University Medical Center, Nashville, Tennessee, United States.
LA  - eng
PT  - Journal Article
DEP - 20240205
PL  - United States
TA  - Blood Adv
JT  - Blood advances
JID - 101698425
SB  - IM
EDAT- 2024/02/05 18:42
MHDA- 2024/02/05 18:42
CRDT- 2024/02/05 15:23
PHST- 2024/01/28 00:00 [accepted]
PHST- 2023/08/26 00:00 [received]
PHST- 2024/01/26 00:00 [revised]
PHST- 2024/02/05 18:42 [medline]
PHST- 2024/02/05 18:42 [pubmed]
PHST- 2024/02/05 15:23 [entrez]
AID - 514814 [pii]
AID - 10.1182/bloodadvances.2023011532 [doi]
PST - aheadofprint
SO  - Blood Adv. 2024 Feb 5:bloodadvances.2023011532. doi: 
      10.1182/bloodadvances.2023011532.